Abstract: A method of treating psoriatic arthritis in a patient having showed an inadequate response to treatment with an anti-TNF therapy by administering an IL-23 specific antibody, e.g., guselkumab, in a clinically proven safe and clinically proven effective amount and the patient achieves significant ACR20/50/70, IGA, HAQ-DI, CRP, SF-36 PCS/MCS, MDA, VLDA, enthesitis, dactylitis, and LEI/dactylitis improvement as measured 16, 24 and 48 weeks after initial treatment.

Abstract: The invention relates to a method of determining the efficacy of the treatment for RA based on two to several characteristics known to correlate with negative outcomes in RA presented in a matrix, as well as a method of determining the efficacy of the treatment for RA based on preparing matrix table comprising two to several covariates which significantly correlate with radiological progression, where the matrix relates this profile of characteristics or covariates to the probability (risk) of negative outcomes under each of the alternative potential treatments, which can be done for a subject, for example, prior to the manifestation of other gross measurements of clinical response.